4902 Eisenhower Boulevard
Suite 125
Tampa, FL 33634
United States
813 286 7900
https://www.oragenics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 5
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Charles L. Pope CPA | Executive Chairman | 112,5k | N/D | 1952 |
Mr. Joseph Michael Redmond | President & Interim Principal Executive Officer | N/D | N/D | 1961 |
Ms. Janet Huffman | CFO, Secretary & Treasurer | 314,9k | N/D | 1972 |
Dr. James P. Kelly M.A., M.D. | Chief Medical Officer & Member of Scientific Advisor | N/D | N/D | N/D |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
L'ISS Governance QualityScore di Oragenics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.